Comparison Arterial Blood Pressure and Cardiac Index-based Hemodynamic Management on Postoperative Myocardial Injury

Sponsor
Istanbul Saglik Bilimleri University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05391087
Collaborator
(none)
84
1
2
6
14

Study Details

Study Description

Brief Summary

The primary aim of this study is to compare mean arterial pressure (MAP) and cardiac index (CI) based intraoperative hemodynamic management in terms of postoperative high sensitive troponin elevation.

The hypothesis of the study is that there will be at least 5ng/L difference between the two groups in terms of troponin elevation occurring in the postoperative period. When power analysis was performed with this primary output, it was calculated that while alpha was 0.05 beta 0.2, 42 patients in each group, a total of 84 patients were required.

Condition or Disease Intervention/Treatment Phase
  • Other: Mean arterial pressure based management
  • Other: Cardiac index based management
N/A

Detailed Description

Fluid therapy will be started as 2-4 ml/kg/h, according to the clinician's decision for the patient. Afterwards, patients will be managed hemodynamically with one of the MAP and CI algorithms.

Targeted fluid therapy will be administered in accordance with the following definitions of normal and algorithms for both groups.

Normal definitions:

MAP: Baseline MAP +/- 20% and MAP>65mmHg Baseline MAP: MAP average in the ward at rest the day before surgery

CI: Baseline CI +/- 20% and CI > 2.2 L/m2/min Baseline CI: CI calculated by MostCare monitor before the anesthesia induction starts

Low MAP intervention If PPV>14, apply 500ml crystalloid If PPV>9 and any additional finding regarding hypovolemia, apply 500ml crystalloid If PPV<10, start/titrate noradrenaline infusion

Low CI intervention If PPV>9, apply mini fluid challenge (MFC). If MFC is positive, apply 500ml crystalloid.

If MFC is negative, evaluate MAP. If MAP is elevated start/titrate remifentanil. If MAP is not elevated start/titrate dopamine/dobutamine in accordance with SVRI

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Comparison of Arterial Blood Pressure and Cardiac Index-based Hemodynamic Management on Postoperative Myocardial Injury in Patients Undergoing Hepatopancreatic Surgery: a Randomized Clinical Trial
Actual Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Mean Arterial Pressure (MAP) Group

Target MAP: Baseline MAP +/- 20% and MAP>65mmHg Baseline MAP: MAP average in the ward at rest the day before surgery Low MAP intervention If PPV>14, apply 500ml crystalloid If PPV>9 and any additional finding regarding hypovolemia, apply 500ml crystalloid If PPV<10, start/titrate noradrenaline infusion

Other: Mean arterial pressure based management
Mean arterial pressure group: Low MAP will be intervened in accordance with the protocol as described in the arm

Active Comparator: Cardiac Index (CI) Group

CI: Baseline CI +/- 20% and CI > 2.2 L/m2/min Baseline CI: CI calculated by MostCare monitor before the anesthesia induction starts Low CI intervention If PPV>9, apply mini fluid challenge (MFC). If MFC is positive, apply 500ml crystalloid. If MFC is negative, evaluate MAP. If MAP is elevated start/titrate remifentanil. If MAP is not elevated start/titrate dopamine/dobutamine in accordance with systemic vascular resistance index (SVRI)

Other: Cardiac index based management
Cardiac index group: Low CI will be intervened in accordance with the protocol as described in the arm. Additionally, if MAP is lower than target MAP along with a normal CI, this will be intervened with noradrenalin infusion/titration

Outcome Measures

Primary Outcome Measures

  1. Postoperative high sensitive troponin change [three days]

    difference between the mean high sensitive troponin elevation between the groups will be evaluated. high sensitive troponin T will be measured one day before the surgery, and daily after the surgery for three days

Secondary Outcome Measures

  1. postoperative myocardial injury incidence [three days]

    high-sensitivity troponin T elevation by at least 5 ng/L from the preoperative concentration to at least 20 ng/L

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients who will undergo pancreatic-hepatic surgery

  2. Patients over 65 years of age or patients over 45 years of age and with at least one of the following comorbidities:

coronary artery disease, Congestive heart failure, moderate to severe heart valve disease, peripheral artery disease Moderate to Severe Pulmonary hypertension, cerebrovascular accident older than 1 month, History of pulmonary embolism more than 1 month old, Diabetes Mellitus, Hypertension

Exclusion Criteria:
  1. Presence of atrial fibrillation, sepsis, pulmonary embolism

  2. Presence of pulmonary embolism, acute coronary syndrome and cerebrovascular accident in the last month

  3. Static respiratory system compliance < 35ml/cmH2O

  4. Patients with preoperative high sensitive Troponin T value >65ng/liter

  5. glomerular filtration rate < 60 ml/min

Exclusion criteria during the protocol:
  1. Newly developed arrhythmia, embolism, sepsis,

  2. Cancellation of planned surgery

  3. Postoperative hepatic failure defined as INR>2

Contacts and Locations

Locations

Site City State Country Postal Code
1 Başakşehir Çam and Sakura City Hospital Istanbul Turkey

Sponsors and Collaborators

  • Istanbul Saglik Bilimleri University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Taner Abdullah, Medical Doctor, Istanbul Saglik Bilimleri University
ClinicalTrials.gov Identifier:
NCT05391087
Other Study ID Numbers:
  • 2021.12.271
First Posted:
May 25, 2022
Last Update Posted:
Jun 15, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 15, 2022